International Sentinel Site Surveillance of Patients with Transfusional Hemosiderosis Treated with Deferasirox in Actual Practice Setting

The oral iron chelator deferasirox is indicated for treatment of chronic iron overload (IOL) resulting from blood transfusions in patients aged ≥2 years. Multiple clinical studies have established the efficacy and safety of deferasirox in transfusion-dependent patients with IOL.

Source: Clinical Lymphoma, Myeloma and Leukemia - August 26, 2016 Category: Hematology Authors: Amal El-Beshlawy, Baba Inusa, David Beneitez, Blanca Xicoy, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Geralyn Gilotti, Mohsen Elalfy Source Type: research